Oncopeptides Q4: Initial take - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Oncopeptides Q4: Initial take - Redeye

{newsItem.title}

Redeye's provides its initial take on Oncopeptides’ year-end report, which came in slightly softer than we had estimated, albeit still showing growth in Pepaxti sales and progress in licensing discussions. We anticipate making moderate revisions to our financial projections and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1084167/oncopeptides-q4-initial-take?utm_source=finwire&utm_medium=RSS

Nyheter om Oncopeptides

Läses av andra just nu

Om aktien Oncopeptides

Senaste nytt